Cisplatin (DDP) is one of the most commonly used chemotherapeutic agents for urological malignancies and is often used to treat small cell carcinoma of the prostate, bladder, renal pelvis, ureter, testicular, penile, and scrotum cancers. Cisplatin is a model of high efficiency and high toxicity among chemotherapeutic drugs. Usage and dosage (1) Intravenous administration 20-30 mg/m2, dissolved in 200-500 mL NS, once a day, 3-5 days a cycle, can be repeated 3-4 cycles or 30 mg/m2, once a day, for 3 days, repeated 3-4 cycles, need appropriate amount of hydration diuretic. Adverse reactions (1) The most serious is nephrotoxicity, manifested as renal tubular damage, hematuria, and elevated blood creatinine 1-2 weeks after drug administration. It is necessary to be vigilant for >90 mg/m2 per day, and there is no other means of prevention except hydration. (2) Severe gastrointestinal reactions: Acute vomiting may occur 1-2 hours after dosing and persist for 1 week, requiring strong antiemetics. (3) Ototoxicity: related to the total amount of drug administered, manifested as tinnitus, deafness, and irreversible high frequency hearing loss. Cisplatin is contraindicated in patients with otitis media. Combination with aminoglycoside antibiotics (streptomycin, gentamicin, etc.) can produce fatal renal failure and cause deafness. (4) Bone marrow suppression is mild: the incidence of dose ≥120 mg/m2 can reach 40%, also overlap with other anticancer drugs in combination chemotherapy bone marrow toxicity, leukocytes <3.5x109/L, platelets <75x109/L need to be cautious.